ClinicalTrials.gg
CompletedNCT03276052Updated Dec 11, 2023Results posted

A Phase I, Open-Label, Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Participants

A Phase 1 interventional study of Aclidinium Bromide 400 μg in Healthy Volunteers, sponsored by AstraZeneca. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-11.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

A Phase I, single centre, open-label study to investigate the pharmacokinetics (PK), safety and tolerability of single and multiple twice daily doses of inhaled Aclidinium Bromide in healthy Chinese male and female subjects.

Read the detailed description

Screening will be performed within 21 days of dosing on Day 1. Eligible participants will be admitted to the trial center on Day -1.

Subjects will receive single dose on Day 1, twice daily regimen is from D5 to D8, and only morning dose will be given on Day 9.

During treatment period, from Day 1 through Day 11 at Visit 2, safety measurements (blood pressure, 12-lead ECG; and AE/SAE monitoring) and blood samples for PK assessments will be collected at predetermined time points.

Clinical laboratory tests (haematology, serum biochemistry and urinalysis) will be performed under fasting conditions at Day -1 at Visit 2.

A follow-up visit will be performed on Day 15.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Pharmacokinetics
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to communicate with medical team and staff, willing to participate in the trial, willing to give written , and comply with the trial restrictions.
  2. Healthy subjects: Chinese men or non-pregnant, non-lactating women, 18 through 45 years old at Visit 1 (Screening).
  3. Have a (BMI) ≥19 kg/m2 and ≤ 26 kg/m2
  4. Resting heart rate ≥ 50 beats per minute (bpm) and ≤ 100 bpm at Visit 1 (Screening) and at admission to the unit on Day -1 at Visit 2.
  5. Non-smoker (never smoked or has not smoked within 2 years prior to the first dose of product [IP]).
  6. Demonstrate satisfactory technique in the use of the DPI at screening.

Exclusion criteria

Exclusion Criteria:

  1. History of any significant drug allergy or to aclidinium bromide or other muscarinic antagonists.
  2. Have abnormal and results on the physical examination, medical history, serum biochemistry, haematology, or urinalysis at Visit 1 (Screening).
  3. Sustained resting systolic blood pressure ≥ 140 or ≤ 90 mmHg and resting diastolic blood pressure ≥ 90 or ≤ 50 mmHg at Visit 1 (Screening) or Day -1 at Visit 2.
  4. (ECG) showing interval (QTc) using Fridericia's correction (QTcF) ≥ 450 msec for male participants and ≥460 msec for female participants as indicated in the centralised reading report assessed at Screening (Visit 1).
  5. Have a history of alcohol or substance abuse within the previous 5 years, as reported by the participants.
  6. Positive results for drugs of abuse at Visit 1 (Screening).
  7. Positive test for surface antigen (HBsAg), antibody and/or (HIV) antibodies at Visit 1 (Screening).
  8. Use of any medication within 2 weeks or within the equivalent time of 5 half-lives of taking the last dose (whichever is longer) before the first dose of IP, or hormonal drug products and traditional Chinese medicines within 30 days before the first dose of IP.
  9. Have consumed caffeine or any grapefruit-containing products within 48 hours or alcohol within 72 hours before Day -1.
  10. Participation in any other clinical investigation using an experimental drug requiring repeated blood or plasma draws within 60 days of Day 1 at Visit 2.
  11. Have participated in a blood/plasma donation or blood loss greater than 400 mL within 90 days, or greater than 200 mL within 30 days prior to screening (Visit 1).
  12. Recent history of a disease or condition that would result in any residual upper respiratory airways/lung inflammatory process or residual limited lung function at the time of Day 1 at Visit 2.
  13. History of confirmed COVID-19 infection.
  14. Have any gastrointestinal, hepatic, or renal condition that might affect the absorption, distribution, biotransformation, or excretion of aclidinium bromide.
  15. Inability to be venipunctured or tolerate venous access as determined by the PI or designee.
  16. Participants unable to give their consent, or participants of consenting age but under guardianship, or vulnerable participants.
  17. In the opinion of the PI, participants who are unlikely to comply with the protocol requirements, instructions, and trial-related restrictions.
  18. Participant is a relative of the Investigator or any sub-investigator, research assistant, pharmacist, trial coordinator, or other staff or directly involved in the conduct of the clinical trial.
  19. Any other conditions that, in the Investigator's opinion, might have indicated the participant to be unsuitable for the study (e.g. confirmed/suspected COVID-19)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Aclidinium Bromide 400 μg

    One inhalation from the 400 μg Aclidinium Bromide inhaler.

    Drug: Aclidinium Bromide 400 μg

Interventions

  • Aclidinium Bromide 400 μg BID inhalation powder. One oral inhalation via Genuair® dry powder inhaler (DPI)

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Characterization of Cmax, taken directly from the individual concentration-time curve after single dose or multiple dose.

    Time frame: Day 1 and Day 9

  2. Time to Reach Maximum Observed Concentration (Tmax)

    Characterization of Tmax, taken directly from the individual concentration-time curve after single dose or multiple dose.

    Time frame: Day 1 and Day 9

  3. Area Under the Concentration-time From Zero to Infinity (AUCinf)

    Characterization of AUCinf (single dose). Area under the concentration time curve from time zero extrapolated to infinity. AUC(0-∞) is estimated by AUC(last) + Clast/λz where Clast is the last observed quantifiable concentration.

    Time frame: Day 1

  4. Area Under the Concentration-time From Time 0 to 12 Hours Post-dose [AUC(0-12)]

    The AUC(0-12) of aclidinium bromide and its metabolites after single dose of aclidinium bromide in healthy Chinese participants is investigated. Description of the AUC(0-12), partial area under the concentration- time curve in the dose interval after single dose or multiple dose.

    Time frame: Day 1 and Day 9

  5. Area Under the Concentration-time From Zero to the Last Quantifiable Concentration (AUClast)

    Characterization of AUClast, taken directly from the individual concentration-time curve after single dose or multiple dose.

    Time frame: Day 1 and Day 9

  6. Half-life Associated With Terminal Slope of a Semi-logarithmic Concentration-time Curve (t½λz)

    Characterization of t½λz, of aclidinium bromide and its metabolites after single and multiple doses of aclidinium bromide in healthy Chinese participants.

    Time frame: Day 1 and Day 9

  7. Apparent Total Body Clearance From Plasma After Extravascular Administration (CL/F)

    Characterization of CL/F, of aclidinium bromide after single and multiple doses of aclidinium bromide in healthy Chinese participants.

    Time frame: Day 1 and Day 9

  8. Volume of Distribution (Apparent) Following Extravascular Administration Based on Terminal Phase (Vz/F)

    Characterization of Vz/F, of aclidinium bromide after single and multiple doses of aclidinium bromide in healthy Chinese participants.

    Time frame: Day 1 and Day 9

  9. Mean Residence Time of the Unchanged Drug in the Systemic Circulation (MRTinf)

    Characterization of MRTinf, of aclidinium bromide after single dose of aclidinium bromide in healthy Chinese participants.

    Time frame: Day 1

  10. Minimum Observed Drug Concentration (Cmin)

    Characterization of Cmin, taken directly from the individual concentration-time curve after single dose or multiple dose.

    Time frame: Day 1 and Day 9

  11. Average Drug Concentration Over a Dosing Interval (Cavg)

    Characterization of Cavg, of aclidinium bromide and its metabolites after multiple doses of aclidinium bromide in healthy Chinese participants.

    Time frame: Day 9

  12. Accumulation Ratio for Cmax [Rac(Cmax)]

    Characterization of Rac(Cmax), of aclidinium bromide and its metabolites after multiple doses of aclidinium bromide in healthy Chinese participants. Rac(Cmax) is caculated as a ratio for Cmax estimated as (ratio of Css,max on Day 9/Cmax on Day 1).

    Time frame: Day 9

  13. Accumulation Ratio for Cmin (Rac[Cmin])

    Characterization of Rac(Cmin), of aclidinium bromide and its metabolites after multiple doses of aclidinium bromide in healthy Chinese participants. Rac(Cmin) is calculated as ratio for Cmin estimated as (ratio of Css, Cmin on Day 9/ Cmin on Day 1)

    Time frame: Day 9

  14. Accumulation Ratio for AUCτ (Rac[AUC])

    Characterization of Rac(AUC), of aclidinium bromide and its metabolites after multiple doses of aclidinium bromide in healthy Chinese participants. Rac(AUC), calculated as ratio of AUC(0-12) on day 9 and AUC0-12 on Day 1.

    Time frame: Day 9

  15. Fluctuation Index During a Dosing Interval (%Fluc)

    Characterization of %Fluc, of aclidinium bromide and its metabolites after multiple doses of aclidinium bromide in healthy Chinese participants. The %Fluc index is estimated as 100 x (Cmax- Cmin)/Cav.

    Time frame: Day 9

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs)

    The safety, and tolerability of aclidinium bromide 400 μg BID after single and multiple dose administration in healthy Chinese participants was evaluated.

    Time frame: From Screening (Day -21 to Day -2) until the follow-up visit (Day 15)

07

Results

Posted Dec 11, 2023

Participant flow

The study was conducted at one study centre in China between 14 October 2021 to 26 November 2021.

Participant flow — Overall Study
MilestoneAclidinium Bromide 400 μg
Started43
Completed20
Not completed23
Withdrew: Withdrawal by subject5
Withdrew: Screening failure (non-fulfilment of inclusion/exclusion criteria)18

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax)

Characterization of Cmax, taken directly from the individual concentration-time curve after single dose or multiple dose.

Time frame:
Day 1 and Day 9
Reported as:
Geometric mean · pg/mL
Maximum Observed Plasma Concentration (Cmax)
pg/mLSingle Dose (Day 1)Multiple Dose (Day 9)
Aclidinium bromide238.6 ± 51.67341.3 ± 40.24
LAS34850 (inactive acid metabolite)3831 ± 24.994891 ± 16.52
LAS34823 (inactive alcohol metabolite)164.0 ± 45.05294.1 ± 39.93
PrimaryTime to Reach Maximum Observed Concentration (Tmax)

Characterization of Tmax, taken directly from the individual concentration-time curve after single dose or multiple dose.

Time frame:
Day 1 and Day 9
Reported as:
Median · Hour
Time to Reach Maximum Observed Concentration (Tmax)
HourSingle Dose (Day 1)Multiple Dose (Day 9)
Aclidinium bromide0.08 (0.08 to 0.10)0.08 (0.08 to 0.10)
LAS34850 (inactive acid metabolite)3.00 (2.00 to 3.00)2.50 (1.50 to 3.00)
LAS34823 (inactive alcohol metabolite)0.08 (0.08 to 0.50)0.08 (0.08 to 0.50)
PrimaryArea Under the Concentration-time From Zero to Infinity (AUCinf)

Characterization of AUCinf (single dose). Area under the concentration time curve from time zero extrapolated to infinity. AUC(0-∞) is estimated by AUC(last) + Clast/λz where Clast is the last observed quantifiable concentration.

Time frame:
Day 1
Reported as:
Geometric mean · h*pg/mL
Area Under the Concentration-time From Zero to Infinity (AUCinf)
h*pg/mLSingle Dose (Day 1)
Aclidinium bromide266.1 ± 59.15
LAS34850 (inactive acid metabolite)29970 ± 17.63
LAS34823 (inactive alcohol metabolite)684.4 ± 48.04
PrimaryArea Under the Concentration-time From Time 0 to 12 Hours Post-dose [AUC(0-12)]

The AUC(0-12) of aclidinium bromide and its metabolites after single dose of aclidinium bromide in healthy Chinese participants is investigated. Description of the AUC(0-12), partial area under the concentration- time curve in the dose interval after single dose or multiple dose.

Time frame:
Day 1 and Day 9
Reported as:
Geometric mean · h*pg/mL
Area Under the Concentration-time From Time 0 to 12 Hours Post-dose [AUC(0-12)]
h*pg/mLSingle Dose (Day 1)Multiple Dose (Day 9)
Aclidinium bromide167.1 ± 40.19357.8 ± 32.28
LAS34850 (inactive acid metabolite)22730 ± 18.6433910 ± 15.33
LAS34823 (inactive alcohol metabolite)438.1 ± 37.261031 ± 25.56
PrimaryArea Under the Concentration-time From Zero to the Last Quantifiable Concentration (AUClast)

Characterization of AUClast, taken directly from the individual concentration-time curve after single dose or multiple dose.

Time frame:
Day 1 and Day 9
Reported as:
Geometric mean · h*pg/mL
Area Under the Concentration-time From Zero to the Last Quantifiable Concentration (AUClast)
h*pg/mLSingle Dose (Day 1)Multiple Dose (Day 9)
Aclidinium bromide208.9 ± 57.23609.4 ± 36.49
LAS34850 (inactive acid metabolite)29010 ± 18.0250370 ± 16.78
LAS34823 (inactive alcohol metabolite)550.4 ± 54.051849 ± 25.49
PrimaryHalf-life Associated With Terminal Slope of a Semi-logarithmic Concentration-time Curve (t½λz)

Characterization of t½λz, of aclidinium bromide and its metabolites after single and multiple doses of aclidinium bromide in healthy Chinese participants.

Time frame:
Day 1 and Day 9
Reported as:
Geometric mean · Hour
Half-life Associated With Terminal Slope of a Semi-logarithmic Concentration-time Curve (t½λz)
HourSingle Dose (Day 1)Multiple Dose (Day 9)
Aclidinium bromide13.50 ± 91.5521.42 ± 25.63
LAS34850 (inactive acid metabolite)8.322 ± 26.8312.68 ± 18.98
LAS34823 (inactive alcohol metabolite)9.964 ± 42.9817.66 ± 12.35
PrimaryApparent Total Body Clearance From Plasma After Extravascular Administration (CL/F)

Characterization of CL/F, of aclidinium bromide after single and multiple doses of aclidinium bromide in healthy Chinese participants.

Time frame:
Day 1 and Day 9
Reported as:
Geometric mean · Liter/hour
Apparent Total Body Clearance From Plasma After Extravascular Administration (CL/F)
Liter/hourSingle Dose (Day 1)Multiple Dose (Day 9)
Apparent Total Body Clearance From Plasma After Extravascular Administration (CL/F)1503 ± 59.151118 ± 32.28
PrimaryVolume of Distribution (Apparent) Following Extravascular Administration Based on Terminal Phase (Vz/F)

Characterization of Vz/F, of aclidinium bromide after single and multiple doses of aclidinium bromide in healthy Chinese participants.

Time frame:
Day 1 and Day 9
Reported as:
Geometric mean · Liter
Volume of Distribution (Apparent) Following Extravascular Administration Based on Terminal Phase (Vz/F)
LiterSingle Dose (Day 1)Multiple Dose (Day 9)
Volume of Distribution (Apparent) Following Extravascular Administration Based on Terminal Phase (Vz/F)29280 ± 45.5334550 ± 40.89
PrimaryMean Residence Time of the Unchanged Drug in the Systemic Circulation (MRTinf)

Characterization of MRTinf, of aclidinium bromide after single dose of aclidinium bromide in healthy Chinese participants.

Time frame:
Day 1
Reported as:
Geometric mean · Hour
Mean Residence Time of the Unchanged Drug in the Systemic Circulation (MRTinf)
HourSingle Dose (Day 1)
Mean Residence Time of the Unchanged Drug in the Systemic Circulation (MRTinf)13.45 ± 95.18
PrimaryMinimum Observed Drug Concentration (Cmin)

Characterization of Cmin, taken directly from the individual concentration-time curve after single dose or multiple dose.

Time frame:
Day 1 and Day 9
Reported as:
Geometric mean · pg/mL
Minimum Observed Drug Concentration (Cmin)
pg/mLSingle Dose (Day 1)Multiple Dose (Day 9)
Aclidinium bromide3.251 ± 56.2511.55 ± 41.22
LAS34850 (inactive acid metabolite)647.8 ± 20.841223 ± 19.34
LAS34823 (inactive alcohol metabolite)14.82 ± 31.5343.03 ± 28.55
PrimaryAverage Drug Concentration Over a Dosing Interval (Cavg)

Characterization of Cavg, of aclidinium bromide and its metabolites after multiple doses of aclidinium bromide in healthy Chinese participants.

Time frame:
Day 9
Reported as:
Geometric mean · pg/mL
Average Drug Concentration Over a Dosing Interval (Cavg)
pg/mLMultiple Dose (Day 9)
Aclidinium bromide29.82 ± 32.28
LAS34850 (inactive acid metabolite)2826 ± 15.33
LAS34823 (inactive alcohol metabolite)85.95 ± 25.56
PrimaryAccumulation Ratio for Cmax [Rac(Cmax)]

Characterization of Rac(Cmax), of aclidinium bromide and its metabolites after multiple doses of aclidinium bromide in healthy Chinese participants. Rac(Cmax) is caculated as a ratio for Cmax estimated as (ratio of Css,max on Day 9/Cmax on Day 1).

Time frame:
Day 9
Reported as:
Geometric mean · Ratio
Accumulation Ratio for Cmax [Rac(Cmax)]
RatioAclidinium Bromide 400 μg
Aclidinium bromide1.431 ± 44.18
LAS34850 (inactive acid metabolite)1.277 ± 20.40
LAS34823 (inactive alcohol metabolite)1.794 ± 45.61
PrimaryAccumulation Ratio for Cmin (Rac[Cmin])

Characterization of Rac(Cmin), of aclidinium bromide and its metabolites after multiple doses of aclidinium bromide in healthy Chinese participants. Rac(Cmin) is calculated as ratio for Cmin estimated as (ratio of Css, Cmin on Day 9/ Cmin on Day 1)

Time frame:
Day 9
Reported as:
Geometric mean · Ratio
Accumulation Ratio for Cmin (Rac[Cmin])
RatioAclidinium Bromide 400 μg
Aclidinium bromide3.554 ± 50.32
LAS34850 (inactive acid metabolite)1.888 ± 22.90
LAS34823 (inactive alcohol metabolite)2.903 ± 37.70
PrimaryAccumulation Ratio for AUCτ (Rac[AUC])

Characterization of Rac(AUC), of aclidinium bromide and its metabolites after multiple doses of aclidinium bromide in healthy Chinese participants. Rac(AUC), calculated as ratio of AUC(0-12) on day 9 and AUC0-12 on Day 1.

Time frame:
Day 9
Reported as:
Geometric mean · Ratio
Accumulation Ratio for AUCτ (Rac[AUC])
RatioAclidinium Bromide 400 μg
Aclidinium bromide2.141 ± 37.64
LAS34850 (inactive acid metabolite)1.492 ± 16.84
LAS34823 (inactive alcohol metabolite)2.354 ± 40.94
PrimaryFluctuation Index During a Dosing Interval (%Fluc)

Characterization of %Fluc, of aclidinium bromide and its metabolites after multiple doses of aclidinium bromide in healthy Chinese participants. The %Fluc index is estimated as 100 x (Cmax- Cmin)/Cav.

Time frame:
Day 9
Reported as:
Geometric mean · Percentage
Fluctuation Index During a Dosing Interval (%Fluc)
PercentageMultiple Dose (Day 9)
Aclidinium bromide1102 ± 34.70
LAS34850 (inactive acid metabolite)128.9 ± 14.90
LAS34823 (inactive alcohol metabolite)289.2 ± 35.31
SecondaryNumber of Participants With Adverse Events (AEs)

The safety, and tolerability of aclidinium bromide 400 μg BID after single and multiple dose administration in healthy Chinese participants was evaluated.

Time frame:
From Screening (Day -21 to Day -2) until the follow-up visit (Day 15)
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsAclidinium Bromide 400 μg
Any AE5
Any AE with outcome = death0
Any SAE (including events with outcome = death)0
Any AE leading to discontinuation of IP0
Any AE of special interest1

Adverse events

Collected over From Screening (Day -21 to Day -2) until the follow-up visit (Day 15). Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aclidinium Bromide 400 μg0/20 (0%)0/20 (0%)5/20 (25%)
Most frequent other events
Most frequent other events
EventAclidinium Bromide 400 μg
SyncopeNervous system disorders1/20
Atrial escape rhythmCardiac disorders1/20
Orthostatic hypotensionVascular disorders1/20
Throat irritationRespiratory, thoracic and mediastinal disorders1/20
Mouth ulcerationGastrointestinal disorders1/20
Alanine aminotransferase increasedInvestigations1/20
Aspartate aminotransferase increasedInvestigations1/20

Baseline characteristics

The safety analysis set included all participants who received at least 1 dose of IP and for whom any safety post-dose data were available.

Age, Continuous
Age, Continuous(years)Aclidinium Bromide 400 μg
Mean27.15 ± 5.20
Sex: Female, Male
Sex: Female, Male(Participants)Aclidinium Bromide 400 μg
Female9
Male11
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Aclidinium Bromide 400 μg
Asian/Chinese20
08

Study locations

1 site
  • Research Site
    Chengdu, 610000, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Nov 2021, 1 month.

Results were first posted in Dec 2023, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2017
First posted
Sep 8, 2017
StartActual
Oct 14, 2021
Primary completionActual
Nov 26, 2021
CompletionActual
Nov 26, 2021
Results first posted
Dec 11, 2023
Last update
Dec 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03276052
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 8, 2017
Start date
Oct 14, 2021
Primary completion
Nov 26, 2021
Completion
Nov 26, 2021
Results posted
Dec 11, 2023
Last update
Dec 11, 2023

Study contacts

Weimin Li
principal investigator · West China Hostial, Sichuan University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aclidinium bromide

Start the discussion